Introduction

In Japan, the United States and western Europe, chronic infection with hepatitis C virus (HCV) is the leading cause of death from liver disease and the leading indication for adult liver transplantation (LT) [1,2]. Reinfection of the allograft with HCV is inevitable in HCV-positive LT recipients [2], though this reinfection is avoidable if antiviral treatment accomplishes a sustained virological response (SVR) before LT. In a few cases, histopathological recurrence is minimal and non-progressive. However, disease course frequently evolves into cirrhosis with transplanted graft loss [2].

History of fibrosing cholestatic hepatitis (FCH)

FCH is an often fatal form of hepatitis B or C in patients receiving immunosuppressive treatment [1-3]. This condition was originally described in hepatitis B virus-infected recipients after LT [3]. The term FCH was first coined in 1991 to describe a severe and fulminant form of recurrent hepatitis B in LT recipients [4,5], although cases with similar presentations of clinical and pathological findings had been recorded earlier [6,7]. It has also been described using other names, such as “fibrosing cytolytic liver failure” [8] and “fibroviral hepatitis” [9].

FCH C after LT

Approximately 10% of HCV-positive recipients will develop FCH after LT [1,2,10,11]. FCH is clinically characterized as marked jaundice with cholestatic hepatic dysfunction and high titers of viremia [2]. Pathologically, FCH manifests as marked hepatocyte swelling, cholestasis, perportal peritrabecular fibrosis and only mild inflammation [1-3]. This progressive form of disease usually involves acute liver failure, and rapidly results in graft loss after LT [1-3].
Conventional therapy with pegylated interferon (IFN) and ribavirin

A therapeutic goal of chronic HCV infection is a SVR that reflects HCV eradication [12]. Historically, treatments for recurrent hepatitis C have been limited by their low rate of success and high rate of side effects [1-3]. Until recently, the standard care for treatment of recurrent hepatitis C was combination therapy with IFN and ribavirin [1-3]. Dual therapy with these agents improved LT results [13]. However, this treatment induced a high rate of side effects, with an SVR rate of only approximately 30% [1,2]. Over the past few years, several new treatments with a high rate of SVR and lacking IFN have emerged for the treatment of hepatitis C [1,2]. Furthermore, these treatments have a lower incidence of side effects [1,2].

Advanced strategy with direct-acting antivirals (DAAs)

This review focuses on recent therapeutic advances and highlights areas of ongoing research. Therapeutic strategies against HCV have dramatically improved with the recent availability of DAAs including telaprevir, boceprevir, sofosbuvir, simeprevir, daclatasvir, ledipasvir, paritaprevir, ombitasvir, and dasabuvir [1,2,12]. Carefully selected combinations of these DAAs offer the potential for highly effective all-oral safe regimens even for patients with decompensated cirrhosis or LT recipients [12]. These treatments have become the standard care in the pre-transplant setting [1,2], and, moreover, have an expanding role for post-transplant patients [1,2,12]. To date, only a few cases of successfully treated FCH C after LT by DAAs have been reported [14-18] (Table 1).

HCV viremia after LT

Allograft injuries caused by HCV viremia occur immediately after graft recirculation [19], and 95% of LT patients develop recurrent hepatitis C [2]. Acute infection with detectable HCV viremia manifests in approximately 60% of LT recipients [1,2,20]. HCV infection in LT recipients is characterized by high viral titers, characteristic histological changes, and variable transamininits [1-3,21]. The levels of viremia are generally higher than before LT [22]. Recently, a novel non-invasive technique (hepatic elastography) was developed, which appears to correlate well with the stage of fibrosis. This technique can detect the degree of fibrosis (F≥2) from 6 months after LT, and has an excellent diagnostic capacity at 12 months after LT [23].

Definitive diagnosis of FCH C

The diagnosis of FCH C is mainly made based on histopathological assessment [3,24]. Histopathological confirmation is necessary to establish a diagnosis of HCV recurrence, as well as enabling assessment of the degree of activity and a periodic follow up of disease progression [2,3]. This not only provides information about the prognosis, but also establishes the differential diagnosis with other complications, such as rejection, biliary disease or vascular obstruction [2,25,26]. The criterion of definitive diagnosis of FCH C after LT has been already established [1,27] (Table 2).

| Table 1 | Definitive diagnosis of fibrosing cholestatic hepatitis (FCH) C after liver transplantation (LT) |
|----------------------------------------------|
| Post-transplant FCH C should be made upon the fulfillment of all of the following criteria (a-f) |
| (a) More than 1 month after LT |
| (b) Serum level of total bilirubin >6 mg/dL. |
| (c) Serum levels of alkaline phosphatase and γ-glutamyltransferase >5 times the upper limit of normal range |
| (d) The presence of characteristic histopathology on liver needle biopsy |
| - Ballooning of hepatocytes |
| - Absence of inflammation |
| - Cholangiocellular proliferation without bile duct loss |
| (e) Very high serum levels of HCV-RNA |
| (f) Absence of surgical biliary complications and absence of evidence of hepatic artery thrombosis |

Recurrence hepatitis C in LT recipients

The rate of fibrosis progression is not uniform, and may change over time [21]. Morbidity and mortality rates are increased in HCV-positive recipients, and both allograft and patient survivals are reduced in LT recipients with recurrent hepatitis C compared with HCV-negative recipients [1,2,21]. Severe recurrent hepatitis C can manifest in two ways: as a chronic recurrent hepatitis C or as aggressive FCH C [2,27]. From the viewpoint of a donor pool, recurrent hepatitis C puts further strain on the donor shortage [1], because HCV infection is responsible for approximately 30-40% of re-transplantations [1,2].

FCH usually does not occur until a couple of months after LT [3], although it can occur much earlier in re-transplanted recipients [6,7]. During the LT procedure, intraoperative blood loss is significant, and has a similar effect to phlebotomy on reducing HCV viremia [28]. However, it also decreases HCV antibody levels, which is not advantageous for HCV control. We have no conclusive opinion on the effect of intraoperative blood loss on the onset of recurrent hepatitis C.

Therapeutic strategies in LT recipients

Two therapeutic strategies for HCV can be adopted once the patient has received LT [1,2,29]. The aim of preemptive therapy is to eliminate HCV before the appearance of hepatic lesions [2,29]. The potential advantage of treating recipients at an
early stage, usually from the first month after LT, is the absence of severe graft involvement or fibrosis [2]. However, during this stage, patients are still recovering from surgery and are receiving multiple drugs and high doses of immunosuppressants, thus they have a greater risk of rejection, so that postponing antiviral therapy is recommended [2,30,31]. Although this treatment is effective in 1-13% of cases, 35% of patients with this option require drug withdrawal because of intolerance or side effects [31]. Recipients with a history of aggressive infection or who are co-infected may be candidates for early treatment provided the presence of rejection is excluded.

However, treatment can be delayed until after recurrent hepatitis C, and this is the most widely used strategy. It involves initiating antiviral therapy once the histopathological consequences of recurrent hepatitis C have been detected by a histopathological investigation of the allograft [2,29]. In this later state, the recipient receives fewer immunosuppressants, and usually has a better clinical and analytical status, which permits antiviral treatment to be optimized and is efficient in 20-40% of cases [32-35]. Even so, approximately 30% of recipients require early withdrawal of the treatment, and approximately 70% require the dose of antivirals to be minimized [32-35]. This reduced exposure to the treatment, together with greater viral replication and unfavorable genotypes, explains the reduced treatment response compared with non-transplanted patients [36].

Thus, treatment strategies should be individualized, and should consider patient comorbidities (renal failure, hyperglycemia), graft function, history of rejection, and HCV characteristics [2,37]. As described above, therapeutic strategies after LT have changed from dual therapy with IFN and ribavirin [1-3] to DAAs without IFN [1,38].

**Predictors of recurrent hepatitis C after LT**

High viral loads in the first 3 months after LT were associated with the severity of recurrent hepatitis C [10], and the level of HCV-RNA at 2 weeks after LT is an important risk factor of FCHC after LT [10]. Previously, we routinely performed splenectomy in HCV-positive recipients, because the side effect of pancytopenia often prevented treatment with IFN after LT [29,38]. Splenectomy is not a standard practice in LT for HCV-positive patients, and splenectomy is stated as just a historic reason. The necessity of splenectomy in HCV-positive recipients will be answered by the many ongoing studies in the coming year, because treatment with DAAs does not cause pancytopenia. To overcome the inevitable insufficiency of allograft size during adult living-donor LT, we intentionally establish portal vein pressure (PVP) under 15 mmHg [39,40]. From the viewpoint of recurrent hepatitis C, hepatic venous portal pressure gradients (HVPGs) are good predictors of clinical decompensation due to recurrent hepatitis C, with only 2% of patients with a normal HVPG and 67% of patients with abnormal HVPG progressing to decompensation [41]. The

**Typical findings of FCHC in the transplanted allograft**

Histopathological findings are characterized as lobular infiltrates, hepatocyte necrosis and fatty infiltration (Fig. 1). Hepatocyte ballooning and cholestasis are observed. Feathery degeneration of hepatic parenchyma caused by cholestasis is confirmed. Apoptotic hepatocytes were also observed. Increased numbers of inflammatory cells infiltrated into the periportal area, and piecemeal necrosis is observed. These damages result in the bridging fibrosis. During a recovery term from FCHC, apoptotic hepatocytes and inflammatory infiltration at the periportal area decreased, and finding of chronic hepatitis C which manifested as spotty and patchy necrosis.

In this case, HCV-ribonucleic acid (HCV-RNA) level increased. Serum levels of aspartate transaminase, alanine aminotransferase, total bilirubin and γ-glutamyltransferase peaked as 157 U/L, 311 U/L, 19.2 mg/dL and 269 U/L, respectively. Direct bilirubin was dominant for jaundice.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Transplantation</th>
<th>Treatments after LT</th>
<th>Case number</th>
<th>Rate of SVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forns et al, 2015 [14]</td>
<td>LT</td>
<td>Sofosbuvir</td>
<td>92</td>
<td>0.59</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ribavirin (Pegylated interferon)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delabaudiere et al, 2015</td>
<td>Combined</td>
<td>Pegylated interferon</td>
<td>1</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>transplantation</td>
<td>Ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(liver and kidney)</td>
<td>Sofosbuvir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al Nahdi et al, 2013</td>
<td>LT</td>
<td>Boceprevir</td>
<td>1</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pegylated interferon</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saab et al, 2015 [17]</td>
<td>LT</td>
<td>Sofosbuvir</td>
<td>10</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leroy et al, 2015 [18]</td>
<td>LT</td>
<td>Sofosbuvir</td>
<td>15</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daclatasvir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leroy et al, 2015 [18]</td>
<td>LT</td>
<td>Sofosbuvir</td>
<td>8</td>
<td>0.88</td>
</tr>
</tbody>
</table>

SVR, sustained virological response
PVP value during LT might have been an informative predictor, nevertheless this value is not relevant to the long term outcome. Only indirect measurements of PVP with HVPG after LT have been correlated with prognosis [42]. Currently, a liver stiffness which reflects the degree of liver fibrosis can be measured by a non-invasive, rapid, quantitative and low-cost method, and this reliable value have been correlated with HVPG [43].

From the viewpoint of hepatitis recurrence, several donor factors, especially donor graft steatosis and older donor age, are associated with an earlier and more severe recurrence of hepatitis C [2,44].

**Is an assessment of Child-Pugh score for DAA induction necessary for allograft dysfunction after LT?**

Child-Pugh score is used to predict the outcome of surgery in cirrhotic patients in general, and more recently, to stratify patients on the waiting list for LT [52]. Then, a simple question arises. Even if serum levels of alanine aminotransferase and the METAVIR system for histologic findings in chronic hepatitis C can be used in transplanted allografts [53,54], is an assessment of the Child-Pugh score necessary even in allograft dysfunction after LT?

Initially, cirrhosis with a Child-Pugh score of B or C contraindicates these drugs because of side effects. When there is a decision against using FCH, allograft dysfunction is severe if based on the Child-Pugh score. Even though the Child-Pugh scoring system is useful for assessing liver cirrhosis, it is not suitable for allograft dysfunction after LT. Currently, new DAAs are safe and effective with few side effects, even in a majority of Child's B and C class, when properly selected. The issues here are the reduced efficacy in advanced cirrhosis and in severe renal impairment [12]. The DAAs should be aggressively introduced for FCH C in LT recipients, and that they might improve the clinical course of patients.

**Discussion**

Although FCH is a rare variant of viral hepatitis, it should be emphasized that a prompt diagnosis is important for the management of adult recipients after LT. Histopathological examination and HCV-RNA measurement should be performed in the event of unexplained laboratory findings and/or intractable ascites [1-3].

Hepatitis C recurrence continues to present a major challenge in LT [1-3]. Despite recent advances, the results in recipients with recurrent hepatitis C are not satisfactory, mainly because of a recurrence of the primary disease and a lack of availability of an efficient prophylactic therapy [1,2]. The last few years have seen the introduction of DAAs [1,2]. Carefully considered DAA induction provides hope for the development of new protocols that are safer and more effective, even in post-transplant situations.
Recent researchers documented excellent results of DAAs, especially in the treatments for patients with hepatitis C before LT. Sofosbuvir-based antiviral therapy is highly effective even in recurrent hepatitis C after LT [55,56], and the SVR rate of sofosbuvir-based therapy was reported as >90% even for hepatitis C in LT recipients [55]. In the recent data for hepatitis C patients, the SVR rates of sofosbuvir/daclatasvir [18,57] and sofosbuvir/ledipasvir [58,59] were reported as 95-100% and 90-97%, respectively. However, these SVR rates were mainly investigated in patients before LT. Moreover, these researchers focused on patients with hepatitis C, not with FCH. There are only a few reports of successful treatments with DAAs for LT recipients with FCH which had fulfilled with diagnostic criterion [14-18] (Tables 1, 2). In the era of all oral therapies with DAAs, no recipients who undergoes LT for HCV-related cirrhosis should have their graft failures because of recurrent hepatitis C [56].

We know that some DAAs should not be used in patients with Child C cirrhosis and/or severe renal impairment. However, the Child-Pugh score is not suitable for the assessment of allograft dysfunction after LT. We all respect health insurance systems around the world. However, even if the broad application of DAAs is unfortunately limited by their high costs [58,60], we suggest that DDAs should be carefully but aggressively induced for fatal FCH C even in LT recipients. We hope this review will be informative for those who care for post-transplant patients with fatal FCH C.

Acknowledgment

We are grateful to Shigeo Nakamura and Yosie Shimoyama (Department of Pathology, Nagoya University Hospital, Nagoya, Japan), for their special supports.

References